Demographic findings of the patients and their response to RTX treatment
| Group 1 | Group 2 | All patients | |
|---|---|---|---|
| (ILD with short duration and naive to treatment) | (ILD with long duration and previous IS therapy) | ||
| Number of patients | 4 (22.2%) | 14 (77.7%) | 18 |
| Sex (F/M) | 3/1 | 13/1 | 16/2 |
| Mean disease duration | 2±0.8 SD years | 10.2±9.8 SD years | 8.3±9.3 SD years |
| Follow-up time after initiation of RTX | 12.2±6.8 SD months | 21±12.4 SD months | 19±11.8 SD months |
| Baseline FVC% | 69.2±20.9 | 65.1±14 | |
| Last FVC% | 66.7±13 | 61.6±19.6 | |
| Baseline DLCO% | 57.7±24.1 | 43.5±12.2 | |
| Last DLCO% | 52±18 | 41.2±21.8 | |
| Outcome: Stable/Improvement (n) | 2 | 7 | 9 |
| Worsening (n) | 2 | 5 | 7 |
| Death | 0 | 1 | 1 |
| Unable to do PFT (n) | 0 | 1 | 1 |